
Opinion|Videos|October 3, 2024
Clinical Impact of Patient-Reported Outcomes in cGVHD
Medical experts discuss the role of patient-reported outcomes in cGVHD.
Advertisement
Video content above is prompted by the following:
- What is the role of patient-reported outcomes (PROs) to measure symptom burden, adverse effect burden, and quality of life and treatment response in cGVHD in your practice?
Which PRO measures are most useful for evaluating disease improvement in cGVHD?
- What do results from recently published PRO data for belumosudil show (Lee SJ, et al. Transplant Cell Ther. 2022)?
Also summarize data with ruxolitinib (Zeiser R, et al. N Engl J Med. 2021) and FDA analysis of ibrutinib PRO data (King-Kallimanis BL, et al. Qual Lif Res. 2020).
- How can available PRO data be utilized in clinical practice to improve quality of life of patients with cGVHD?
Advertisement
Related to this article

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.

The EC approved every-6-week maintenance dosing and shorter 350-mg infusions for cemiplimab across all 6 EU indications.

Faculty convened at an OncLive Scientific Interchange and Workshop to guide oncology fellows through designing a cancer clinical trial development program, from concept to approval.

The FDA granted priority review to sonesitatug vedotin for previously treated CLDN18.2-positive advanced gastroesophageal cancers.

UCLA Health performs its first single-port robotic lobectomy, using a new technique that could reduce pain and make recovery easier for patients with lung cancer.

Narek Shaverdian, MD, outlines how novel strategies may reshape unresectable stage III NSCLC management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Priority Review to Sonesitatug Vedotin in CLDN18.2+ Gastroesophageal Cancer
2
EC Approves Extended Cemiplimab Dosing in Skin, Lung, and Cervical Cancers
3
Dose Optimization, Evidentiary Bars, and Patient Selection Shape Trial Design in EGFR- and HER2-Mutant NSCLC
4
Defining High-Risk Localized Prostate Cancer and the DASL-HiCaP Trial
5


